Navigation Links
Spherix to Hold Business Update Conference Call December 9, 2010 at 4:30 p.m. Eastern Time
Date:12/6/2010

BETHESDA, Md., Dec. 6, 2010 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will host an investment community conference call beginning at 4:30 p.m. Eastern time on Thursday, December 9, to discuss results of the Company's Phase 3 trial with D-tagatose in Type 2 diabetes and to provide a business update.

Investors and other interested parties are invited to listen to the call by dialing (888) 563-6275 from the U.S. or (706) 634-7417 from outside the U.S.  The call also will be available on the Investors section of the Company's website at www.spherix.com.  Slides will accompany the conference call, and will be available in the Investors section of www.spherix.com.

A telephone replay of the conference call will be available for on-demand listening shortly after the completion of the call until 11:59 p.m. Eastern time on December 16, 2010 by dialing (800) 642-1687 from the U.S. or (706) 645-9291 from outside the U.S., and entering access code 29797553.  A replay also will be available at www.spherix.com.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research.  The Company now leverages its scientific and technical expertise and experience through its two subsidiaries – Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics is dedicated to development of D-tagatose and recently completed a Phase 3 clinical trial to study the use of D-tagatose as a treatment
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
2. Spherix Transfers Stock Listing to Nasdaq Capital Market
3. Spherix Reports 3rd Quarter Earnings
4. Spherix Announces 2008 Financial Results
5. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
6. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
7. Spherix to Exhibit at the BIO 2009 International Convention
8. Spherix Regains Full NASDAQ Compliance
9. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
10. Spherix Announces Termination of Arla License Agreement
11. Spherix Reports Second Quarter 2009 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015 According ... Market by Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), ... Labs, Research Institutes) - Analysis & Global Forecast ... the global Antibody Production Market for the forecast ... expected to reach $2.572 Billion by 2019 from ...
(Date:4/30/2015)... 2015 Spirax Sarco, the leader in ... to announce that for the first time in the ... of a Queen’s Award for Innovation – the UK’s ... manufacture of a unique flowmeter. , The Spirax Sarco ... traditional steam flow measurement. The device provides reliable, ...
(Date:4/30/2015)... , April 30, 2015   Tamir Biotechnology ... today an update on its Ebola antiviral therapy program. ... leading candidates, TMR004, is currently being evaluated and considered ... the battle against Ebola. During the first quarter of ... Leadership Meeting To Accelerate The Evaluation of Potential Treatments ...
(Date:4/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), an ... has commenced an underwritten public offering of its common ... a 30-day option to purchase up to an additional ... in the public offering. The offering is subject to ... to whether or when the offering may be completed, ...
Breaking Biology Technology:Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... ... in Prima BioMed Ltd (ASX:PRR), an Australian Securities Exchange-listed oncology biotechnology company. KTA ... Investors, LLC on the transaction. A copy of Prima BioMed Ltd,s public announcement ... ...
... ... Dr. Rebecca Fitzgerald, known among her medical colleagues as the "Sculptra guru" here in the ... at this year,s 4 day SDEF Cosmetic Dermatology Seminar held in Santa Monica, Ca. ... Los Angeles, Ca (PRWEB) ...
... multiple times a day can be difficult for patients to ... 1 to 7 percent of the dose is actually absorbed ... PhD, director of the Laboratory for Biomaterials and Drug Delivery ... can gradually dispense a constant amount of medication to the ...
Cached Biology Technology:KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd 2Looking Older Than You Are May Have Little to Do With Wrinkles 2Looking Older Than You Are May Have Little to Do With Wrinkles 3A drug-dispensing contact lens 2
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... 2013 - BGI Health and ACIBADEM Healthcare Group ... Molecular Biology, signed a Memorandum of Understanding (MoU) ... to Turkey and improving Turkish reproductive healthcare. This ... technologies in the areas of Monogenic disorders, personalized ...
... do woolly mammoths wandering around the ancient spruce ... with predicting how species could respond to climate ... Center for Environmental Science,s Appalachian Laboratory, along with ... University of California-Merced, have received a three-year, $670,000 ...
... do nerve cells -- which can each be up to ... falling apart? Axons, the long, cable-like projections on neurons, ... molecular building block of the cell skeleton. The finding, which ... was reported in the April 10 issue of Neuron ...
Cached Biology News:BGI Health forms partnership with ACIBADEM hospital on genetic disease testing 2Scientists look to ancient past to better predict how species may respond climate change 2Scientists learn what makes nerve cells so strong 2
Laminin beta-1/gamma-1 (612C10)...
HSV 1 IgM...
100 ug affinity purified rabbit anti-JIP-1 polyclonal antibody. Reacts with mouse and rat. Perform well in Western blotting. Other applications have not been tested. Storage Temperature: -20C Shi...
Epstein-Barr Virus (EBV) (EBNA-1)...
Biology Products: